COMMUNIQUÉS West-GlobeNewswire

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
02/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ( [...]
Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference
02/10/2025
CUPERTINO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Premier Health Reports AMP Decision Regarding Subsidiaries in Quebec
02/10/2025
MONTRÉAL, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “ Company ” or “ Premier Health ”), a leading Canadian health tech company, today announced that its subsidiaries, Code Bleu, [...]
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
02/10/2025
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) [...]
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
02/10/2025
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX ® 3-71 tablet exhibits superior pharmacokinetics compared to the current immediate- [...]
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
02/10/2025
– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: [...]
Ocugen to Present at Industry and Investor Conferences in October 2025
02/10/2025
MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive [...]
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
02/10/2025
ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct. 02, 2025 (GLOBE [...]
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
02/10/2025
AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutation AAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue recruiting in our STELLA [...]
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
02/10/2025
SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary [...]
Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder
02/10/2025
DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before the end of 2025 Trial builds on positive Phase 1 study that showed [...]
George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil
02/10/2025
Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, [...]
Bimergen Energy Secures $50 Million for Battery Energy Storage Project Development
02/10/2025
Newport Beach, CA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation [ OTCQB: BESS ], (“the Company” or “Bimergen”), a developer of utility-scale battery energy storage solutions and an independent power [...]
Immuron Letter to Shareholders – Projects Update
02/10/2025
Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products Travelan ® Clinical Study: Topline results from the Travelan ® clinical study [...]
Pennant Completes Purchase of Tennessee, Georgia and Alabama Operations from UnitedHealth Group and Amedisys
02/10/2025
EAGLE, Idaho, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today [...]
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
02/10/2025
STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
02/10/2025
Utrecht, The Netherlands, October 2, 2025 – AM-Pharma B.V. today announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention of [...]
Precision Neuroscience Reports First High-Bandwidth Brain–Computer Interface Achieved Without Open Surgery
02/10/2025
Study in Nature Biomedical Engineering details Precision’s surface-based system and shows results from the first five patients NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), [...]
Igyxos Biotherapeutics Awarded EUR 5.7 Million from the French Government to Accelerate Development of its First-in-class Monoclonal Antibody for the Treatment of Infertility
02/10/2025
TOURS, France, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced that it has secured a [...]

Pages